AR091530A1 - Formulacion farmaceutica liquida de un anticuerpo y acetato - Google Patents
Formulacion farmaceutica liquida de un anticuerpo y acetatoInfo
- Publication number
- AR091530A1 AR091530A1 ARP130102208A AR091530A1 AR 091530 A1 AR091530 A1 AR 091530A1 AR P130102208 A ARP130102208 A AR P130102208A AR 091530 A1 AR091530 A1 AR 091530A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical formulation
- antibody
- acetate
- liquid pharmaceutical
- formulation liquid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Una formulación farmacéutica líquida caracterizada porque comprende un anticuerpo como ingrediente activo a una concentración de entre 200 y 400 mg/ml y acetato. Reivindicación 3: La formulación farmacéutica líquida de las reivindicaciones 1 ó 2 caracterizada porque comprende glicina a una concentración de entre 100 y 500 mM. Reivindicación 11: La formulación farmacéutica líquida de cualquiera de las reivindicaciones 1 a 10 caracterizada porque el anticuerpo es epratuzumab. Reivindicación 14: Un método para reducir la viscosidad de una formulación farmacéutica líquida que contiene una proteína o un anticuerpo, caracterizado porque comprende: a) proporcionar la formulación farmacéutica líquida, y b) añadir acetato hasta una concentración final de entre 20 y 150 mM, caracterizado porque la viscosidad de la formulación farmacéutica líquida se encuentra reducida en comparación con la misma formulación farmacéutica líquida sin acetato.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662621P | 2012-06-21 | 2012-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091530A1 true AR091530A1 (es) | 2015-02-11 |
Family
ID=48745904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102208 AR091530A1 (es) | 2012-06-21 | 2013-06-24 | Formulacion farmaceutica liquida de un anticuerpo y acetato |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20150150979A1 (es) |
| EP (1) | EP2864356A1 (es) |
| JP (1) | JP6157611B2 (es) |
| KR (1) | KR20150032941A (es) |
| CN (1) | CN104520326A (es) |
| AR (1) | AR091530A1 (es) |
| AU (1) | AU2013279347A1 (es) |
| BR (1) | BR112014031841A2 (es) |
| CA (1) | CA2876012A1 (es) |
| CL (1) | CL2014003283A1 (es) |
| CO (1) | CO7170174A2 (es) |
| EA (1) | EA201590061A1 (es) |
| EC (1) | ECSP15002095A (es) |
| HK (1) | HK1205146A1 (es) |
| IL (1) | IL235921A0 (es) |
| MA (1) | MA37777B1 (es) |
| MX (1) | MX2014014717A (es) |
| NZ (1) | NZ702342A (es) |
| PE (1) | PE20150190A1 (es) |
| PH (1) | PH12014502596A1 (es) |
| SG (1) | SG11201407779YA (es) |
| TN (1) | TN2014000498A1 (es) |
| TW (1) | TW201406398A (es) |
| WO (1) | WO2013190047A1 (es) |
| ZA (1) | ZA201409020B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2923844C (en) | 2013-09-11 | 2022-07-26 | Arsia Therapeutics, Inc. | Liquid protein formulations containing organophosphates |
| WO2016054259A1 (en) | 2014-10-01 | 2016-04-07 | Arsia Therapeutics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| CN109496153B (zh) | 2016-05-28 | 2024-04-23 | 印度政府生物技术部独立机构拉吉夫甘地生物技术中心 | 作为肝细胞癌治疗剂的龙葵皂苷b及其衍生物 |
| KR20190078572A (ko) * | 2016-10-31 | 2019-07-04 | 프레제니우스 카비 도이치란트 게엠베하 | 액상의 약학 조성물 |
| ES2933808T3 (es) | 2017-01-11 | 2023-02-14 | Celltrion Inc | Fórmula líquida estable |
| WO2018211517A1 (en) | 2017-05-16 | 2018-11-22 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| GB201719447D0 (en) * | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
| US20230405018A1 (en) * | 2020-11-18 | 2023-12-21 | Bexson Biomedical, Inc. | Flumazenil formulations for subcutaneous injection and methods of treatment using gaba receptor modulators |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6875432B2 (en) * | 2000-10-12 | 2005-04-05 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| PL1610820T5 (pl) * | 2003-04-04 | 2014-01-31 | Genentech Inc | Preparaty zawierające wysokoskoncentrowane przeciwciała i białka |
| NZ561137A (en) * | 2005-03-08 | 2011-09-30 | Pharmacia & Upjohn Co Llc | Stable anti-CTLA-4 antibody compositions with chelating agents |
| JP5419709B2 (ja) * | 2007-01-09 | 2014-02-19 | ワイス・エルエルシー | 抗ｉｌ−１３抗体製剤およびその使用 |
| PL2170390T3 (pl) * | 2007-06-14 | 2019-05-31 | Biogen Ma Inc | Preparaty przeciwciała natalizumab |
| MX2012012743A (es) * | 2010-05-03 | 2012-11-23 | Genentech Inc | Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina. |
| SG185465A1 (en) * | 2010-05-14 | 2012-12-28 | Amgen Inc | High concentration antibody formulations |
| US8754195B2 (en) * | 2010-07-02 | 2014-06-17 | Medimmune, Llc | Antibody formulations |
| CA2832560A1 (en) * | 2011-04-07 | 2012-10-18 | Glaxosmithkline Llc | Formulations with reduced viscosity |
| CA2831572C (en) * | 2011-05-02 | 2019-11-26 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
-
2013
- 2013-06-20 PE PE2014002385A patent/PE20150190A1/es not_active Application Discontinuation
- 2013-06-20 KR KR20147034759A patent/KR20150032941A/ko not_active Application Discontinuation
- 2013-06-20 CA CA2876012A patent/CA2876012A1/en not_active Abandoned
- 2013-06-20 WO PCT/EP2013/062898 patent/WO2013190047A1/en active Application Filing
- 2013-06-20 MA MA37777A patent/MA37777B1/fr unknown
- 2013-06-20 US US14/406,758 patent/US20150150979A1/en not_active Abandoned
- 2013-06-20 MX MX2014014717A patent/MX2014014717A/es unknown
- 2013-06-20 SG SG11201407779YA patent/SG11201407779YA/en unknown
- 2013-06-20 NZ NZ702342A patent/NZ702342A/en not_active IP Right Cessation
- 2013-06-20 EP EP13733246.6A patent/EP2864356A1/en not_active Withdrawn
- 2013-06-20 AU AU2013279347A patent/AU2013279347A1/en not_active Abandoned
- 2013-06-20 CN CN201380032420.1A patent/CN104520326A/zh active Pending
- 2013-06-20 JP JP2015517767A patent/JP6157611B2/ja not_active Expired - Fee Related
- 2013-06-20 EA EA201590061A patent/EA201590061A1/ru unknown
- 2013-06-20 BR BR112014031841A patent/BR112014031841A2/pt not_active IP Right Cessation
- 2013-06-21 TW TW102122152A patent/TW201406398A/zh unknown
- 2013-06-24 AR ARP130102208 patent/AR091530A1/es unknown
-
2014
- 2014-11-21 PH PH12014502596A patent/PH12014502596A1/en unknown
- 2014-11-26 IL IL235921A patent/IL235921A0/en unknown
- 2014-11-28 CL CL2014003283A patent/CL2014003283A1/es unknown
- 2014-11-28 TN TN2014000498A patent/TN2014000498A1/fr unknown
- 2014-12-09 ZA ZA2014/09020A patent/ZA201409020B/en unknown
-
2015
- 2015-01-09 CO CO15004860A patent/CO7170174A2/es unknown
- 2015-01-21 EC ECIEPI20152095A patent/ECSP15002095A/es unknown
- 2015-06-16 HK HK15105706.7A patent/HK1205146A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP15002095A (es) | 2015-11-30 |
| CO7170174A2 (es) | 2015-01-28 |
| BR112014031841A2 (pt) | 2017-06-27 |
| MX2014014717A (es) | 2015-03-06 |
| NZ702342A (en) | 2016-07-29 |
| CL2014003283A1 (es) | 2016-04-01 |
| JP6157611B2 (ja) | 2017-07-05 |
| ZA201409020B (en) | 2016-09-28 |
| AU2013279347A1 (en) | 2014-12-18 |
| EA201590061A1 (ru) | 2015-05-29 |
| PH12014502596A1 (en) | 2015-01-12 |
| US20150150979A1 (en) | 2015-06-04 |
| WO2013190047A1 (en) | 2013-12-27 |
| MA37777B1 (fr) | 2017-07-31 |
| CN104520326A (zh) | 2015-04-15 |
| TW201406398A (zh) | 2014-02-16 |
| JP2015520206A (ja) | 2015-07-16 |
| PE20150190A1 (es) | 2015-02-13 |
| EP2864356A1 (en) | 2015-04-29 |
| CA2876012A1 (en) | 2013-12-27 |
| SG11201407779YA (en) | 2015-02-27 |
| IL235921A0 (en) | 2015-01-29 |
| MA20150436A1 (fr) | 2015-11-30 |
| HK1205146A1 (en) | 2015-12-11 |
| TN2014000498A1 (en) | 2016-03-30 |
| KR20150032941A (ko) | 2015-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091530A1 (es) | Formulacion farmaceutica liquida de un anticuerpo y acetato | |
| CY1122181T1 (el) | Φαρμακοτεχνικη μορφη αντισωματος | |
| ECSP17034829A (es) | Formulación estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf | |
| AR122746A2 (es) | Una formulación farmacéutica líquida estable de anticuerpo | |
| AR097791A1 (es) | Formulaciones de anticuerpos anti-pdl1 | |
| DOP2016000150A (es) | Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos | |
| TN2014000431A1 (en) | Antibody formulatoin | |
| PE20160681A1 (es) | Formulacion de premezcla de dexmedetomidina | |
| BR112014021325A2 (pt) | Formulação farmacêutica líquida e formulação liofilizada | |
| BR112016008576A2 (pt) | Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária | |
| MX2016005395A (es) | Formulacion estable de insulina glulisina. | |
| CO2017007316A2 (es) | Formulación farmacéutica | |
| AR090244A1 (es) | Formulacion de anticuerpo anti-selectina p | |
| PE20210779A1 (es) | NUEVA FORMULACIOìN ESTABLE DE ALTA CONCENTRACIOìN PARA ANTICUERPOS ANTI-FXIa | |
| CL2015000053A1 (es) | Composicion líquida oral pediátrica que comprende nepadutant y tpgs; proceso para prepararla; util en el tratamiento de enfermedades intestinales. | |
| AR102572A1 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf | |
| AR111032A1 (es) | Composición líquida que contiene pradofloxacina | |
| CR20120465A (es) | Formulaciones mejoradas para ingredientes farmaceuticos activos de permeabilidad deficiente | |
| CU20100199A7 (es) | Método y composición farmacéutica para lograr niveles plasmáticos de progesterona requeridos para diferentes indicaciones terapéuticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |